Skip to main content
Premium Trial:

Request an Annual Quote

Synthego: Robert Deans and John Tan

Synthego has appointed Robert Deans as CSO and John Tan as chief operating officer.

Deans has more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise. He previously served in executive roles at BlueRock Therapeutics and Rubius Therapeutics, where he participated in the creation of next-generation therapies through the use of pluripotent stem cell biology and gene editing tools, Synthego said.

Tan has decades of global operations and automation expertise in various technology and life sciences companies, including Amazon and Thermo Fisher Scientific. At Thermo Fisher, he managed global planning, quality, regulatory, procurement, supply chain, and continuous improvement functions across more than 20 sites in the US, Europe, and Asia.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.